Aneurysmal Subarachnoid Hemorrhage Sah Pipeline Insight

DelveInsight’s, “Aneurysmal Subarachnoid Hemorrhage (ASH) – Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Aneurysmal Subarachnoid Hemorrhage (ASH) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Aneurysmal Subarachnoid Hemorrhage (ASH) Understanding

Aneurysmal Subarachnoid Hemorrhage (ASH): Overview

Aneurysmal Subarachnoid Hemorrhage (ASH) (SAH) is a worldwide health burden with high fatality and permanent disability rates. The overall prognosis depends on the volume of the initial bleed, rebleeding, and degree of delayed cerebral ischemia (DCI). The subarachnoid space is the area between the brain and the skull. It is filled with cerebrospinal fluid (CSF), which acts as a floating cushion to protect the brain. When blood is released into the subarachnoid space, it irritates the lining of the brain, increases pressure on the brain, and damages brain cells. At the same time, the area of brain that previously received oxygen-rich blood from the affected artery is now deprived of blood, resulting in a stroke. Aneurysmal Subarachnoid Hemorrhage (ASH) is frequently a sign of a ruptured aneurysm. The common symptoms include: sudden onset of a severe headache (often described as ""the worst headache of my life""), nausea and vomiting, stiff neck, sensitivity to light (photophobia), blurred or double vision, loss of consciousness, and seizures. SAH caused by injury is often seen in the older people who have fallen and hit their head. Among the young, the most common injury leading to SAH is motor vehicle accidents. Five to 10% of strokes are caused by SAH. Treatment for Subarachnoid hemorrhage varies, depending on the underlying cause of the bleeding and the extent of damage to the brain. Treatment may include lifesaving measures, symptom relief, repair of the bleeding vessel, and complication prevention.


"Aneurysmal Subarachnoid Hemorrhage (ASH) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Aneurysmal Subarachnoid Hemorrhage (ASH) pipeline landscape is provided which includes the disease overview and Aneurysmal Subarachnoid Hemorrhage (ASH) treatment guidelines. The assessment part of the report embraces, in depth Aneurysmal Subarachnoid Hemorrhage (ASH) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Aneurysmal Subarachnoid Hemorrhage (ASH) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Aneurysmal Subarachnoid Hemorrhage (ASH) R&D. The therapies under development are focused on novel approaches to treat/improve Aneurysmal Subarachnoid Hemorrhage (ASH).

Aneurysmal Subarachnoid Hemorrhage (ASH) Emerging Drugs Chapters

This segment of the Aneurysmal Subarachnoid Hemorrhage (ASH) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Aneurysmal Subarachnoid Hemorrhage (ASH) Emerging Drugs


Clazosentan: Idorsia Pharmaceuticals

Clazosentan is an intravenous selective endothelin A receptor antagonist being developed by Idorsia Pharmaceuticals, for the treatment of patients with Aneurysmal Subarachnoid Hemorrhage (ASH). In March, 2022 Idorsia has announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after Aneurysmal Subarachnoid Hemorrhage (ASH) (aSAH).


Nicardipine: BIT pharma

A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. Nicardipine is currently being evaluated in Phase II clinical trial for the treatment of patients with aneurysmal subarachnoid haemorrhage.

Further product details are provided in the report……..

Aneurysmal Subarachnoid Hemorrhage (ASH): Therapeutic Assessment

This segment of the report provides insights about the different Aneurysmal Subarachnoid Hemorrhage (ASH) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Aneurysmal Subarachnoid Hemorrhage (ASH)

There are approx. 8+ key companies which are developing the therapies for Aneurysmal Subarachnoid Hemorrhage (ASH). The companies which have their Aneurysmal Subarachnoid Hemorrhage (ASH) drug candidates in the most advanced stage, i.e. Phase III include, Idorsia Pharmaceuticals.

Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Aneurysmal Subarachnoid Hemorrhage (ASH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aneurysmal Subarachnoid Hemorrhage (ASH): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Aneurysmal Subarachnoid Hemorrhage (ASH) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aneurysmal Subarachnoid Hemorrhage (ASH) drugs.

Aneurysmal Subarachnoid Hemorrhage (ASH) Report Insights

  • Aneurysmal Subarachnoid Hemorrhage (ASH) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Aneurysmal Subarachnoid Hemorrhage (ASH) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Aneurysmal Subarachnoid Hemorrhage (ASH) drugs?
  • How many Aneurysmal Subarachnoid Hemorrhage (ASH) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aneurysmal Subarachnoid Hemorrhage (ASH)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aneurysmal Subarachnoid Hemorrhage (ASH) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Aneurysmal Subarachnoid Hemorrhage (ASH) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Aneurysmal Subarachnoid Hemorrhage (ASH): Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Clazosentan: Idorsia Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Nicardipine: BIT pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early stage products (Phase I/II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Aneurysmal Subarachnoid Hemorrhage (ASH) Key Companies

Aneurysmal Subarachnoid Hemorrhage (ASH) Key Products

Aneurysmal Subarachnoid Hemorrhage (ASH)- Unmet Needs

Aneurysmal Subarachnoid Hemorrhage (ASH)- Market Drivers and Barriers

Aneurysmal Subarachnoid Hemorrhage (ASH)- Future Perspectives and Conclusion

Aneurysmal Subarachnoid Hemorrhage (ASH) Analyst Views

Aneurysmal Subarachnoid Hemorrhage (ASH) Key Companies

Appendix

List of Tables

Table 1: Total Products for Aneurysmal Subarachnoid Hemorrhage (ASH)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Aneurysmal Subarachnoid Hemorrhage (ASH)

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Idorsia Pharmaceuticals

• BIT Pharma GmbH

• Akari Therapeutics

• NoNO Inc.

• Grace Therapeutics

• Avilex Pharma

Forward to Friend

Need A Quote